Scienture Holdings, Inc.

Scienture Holdings, Inc. announced and effected a 1-for-25 reverse stock split, which became effective on October 5, 2026. This action was taken primarily to regain compliance with The Nasdaq Stock Market's continued listing rules, specifically the minimum bid price requirement. The reverse stock split adjusted the number of outstanding shares and the exercise prices of equity awards and warrants. Fractional shares will be paid in cash, and the company's stock began trading on a split-adjusted basis on the effective date.

Scienture Holdings reported Q2 2026 revenue of $343,639, a significant increase from zero in the prior year, and a narrowed net loss of $(2.82) million, improving from $(6.72) million. The company's strategic realignment involved divesting legacy subsidiaries to focus on Branded and Specialty Pharma markets. However, the filing includes a cautionary note regarding "substantial doubt about our ability to continue as a going concern," highlighting ongoing financial challenges despite operational improvements.

Scienture Holdings, Inc. announced the commercial launch of REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg, its second FDA-approved commercial product. This high-dose naloxone nasal spray targets the approximately $143 million U.S. naloxone market, fulfilling initial purchase orders to wholesalers. The launch is supported by a national sales force, payer coverage for over 100 million lives, and GPO agreements providing access to more than 5,000 healthcare facilities, aiming to maximize its commercial potential.

Scienture Holdings, Inc. announced the completion of manufacturing for REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg and will begin shipments to U.S. pharmaceutical wholesalers later this month. The company expects the highest-dose FDA-approved naloxone nasal spray to be commercially available for purchase in August. This launch targets the significant U.S. naloxone market, which totals approximately $144 million in annual sales and 9.8 million units, and follows expanded payer access covering over 100 million lives.

Scienture Holdings, Inc. announced significant progress in the commercialization of Arbli™ (losartan potassium oral suspension), including expanded payor coverage for approximately 12.5 million incremental covered lives. The company is also broadening pharmacy access and establishing new channel partnerships to increase patient access across commercial, Medicare, and Medicaid markets. These initiatives aim to strengthen Arbli™'s commercial infrastructure and drive increased prescription volume within the $219 million U.S. losartan market, which sees about 72 million prescriptions annually.

Scienture Holdings announced that REZENOPY™ (naloxone HCl) Nasal Spray 10 mg has been added to a large national health plan's formulary, extending potential coverage to over 100 million lives ahead of its mid-July 2026 commercial launch. This expands access for the highest FDA-approved naloxone dose, targeting the ~$144 million U.S. naloxone market. The company has also secured GPO agreements covering over 5,000 healthcare facilities and expanded its sales team to support nationwide rollout.

Scienture Holdings announced the U.S. Patent and Trademark Office granted U.S. Patent No. 12,622,903 B2 for REZENOPY (naloxone HCl) Nasal Spray 10 mg, effective May 12, 2026, and expiring February 5, 2041. Scienture, through its subsidiary, holds exclusive U.S. commercialization rights for REZENOPY , which received FDA approval on April 19, 2024. The product is the highest FDA-approved dose per nasal spray for naloxone in the U.S. market, addressing a critical public health need in the approximately $141 million annual U.S. naloxone market. The company plans a commercial launch in mid-July.

Scienture Holdings, Inc. announced the resignation of Eric Sherb as Chief Financial Officer, effective May 26, 2026, due to personal reasons and not any dispute with the company. Concurrently, Dr. Narasimhan Mani, currently Co-Chief Executive Officer and President, was appointed Interim CFO. Dr. Mani brings over 25 years of experience in the pharmaceutical industry, including senior management and financial operations roles, and holds an MBA in Finance and Marketing.

Scienture Holdings reported strong financial results for Q1 2026, with revenue increasing 449% year-over-year to $56 thousand and gross profit soaring 7900% to $54 thousand, driven by incremental product orders for ArbliTM. The company also achieved significant operational milestones, including securing a third patent for ArbliTM and an Orange Book-listable patent for REZENOPYTM, alongside formalizing GPO agreements for REZENOPYTM to expand market access. Additionally, Scienture secured $11.0 million in non-dilutive debt financing to support growth and R&D, aiming for anticipated profitability in 2027.

Scienture Holdings, Inc. reported a net loss of $3.40 million for the first quarter of 2026, an increase from $3.06 million in the prior year, despite a significant rise in revenues to $56,325 from $10,258. The company's cash and cash equivalents decreased to $3.54 million from $6.66 million at year-end 2025. Management acknowledges a "going concern" risk due to an accumulated deficit of $83.95 million but expects commercialization of ARBLI (SCN-102) and planned financing to fund operations for the next 12 months. The company completed strategic divestments in 2025 to focus on branded and specialty pharma.